Immune-mediated tumor control by necroptotic cells requires NF-κB activation within dying cells but not MLKL-mediated cell lysis and DAMP release. Immune-mediated.

Slides:

Advertisements

Similar presentations

Identification of combination treatment–responsive effector/memory tumor-infiltrating CD8+ T cell population. Identification of combination treatment–responsive.

Advertisements

Identification of combination treatment–responsive dysfunctional tumor-infiltrating CD8+ T cell population. Identification of combination treatment–responsive.

Fibroblast activation in WT and NFATc2-deficient mice.

Immunologic responses after the MN-mediated cancer immunotherapy.

IFN-γ antagonizes TGF-β in vivo.

LV DNA, genome, and capsid are not required for DC activation and CD8+ T cell priming in vivo. LV DNA, genome, and capsid are not required for DC activation.

Cytotoxicity of MSP samples to normal and cancer cell lines.

VLPs activate DCs and antigen-specific CD8+ T cells via the STING and cGAS pathway. VLPs activate DCs and antigen-specific CD8+ T cells via the STING and.

Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.

LV activation of DCs and subsequent CD8+ T cell priming are dependent on STING and cGAS but not on MyD88, TRIF, or MAVS. LV activation of DCs and subsequent.

Fig. 3 Agonists of innate immunity are effective only when released locally from the hydrogel. Agonists of innate immunity are effective only when released.

Arp2/3-mediated formation of nuclear actin networks is essential for CD4+ T cell effector functions. Arp2/3-mediated formation of nuclear actin networks.

Platelets are required for hFcγRIIA-induced anaphylaxis.

bnmAbs 3D3 and 2D10 specifically block RSV G –induced chemotaxis.

β-Glucans do not modulate epithelial IL-33 or AHR.

Tukey boxplots overlaid on data points from objective and subjective measures, displaying results from study 1. Tukey boxplots overlaid on data points.

MP cells can mediate resistance in infectious models that induce TH1-type immunity. MP cells can mediate resistance in infectious models that induce TH1-type.

T-bethi MP cells produce IFN-γ in response to IL-12.

Fig. 6 In utero injection of inflammatory cytokines or adoptive transfer of activated T cells leads to pregnancy loss. In utero injection of inflammatory.

IFN-γ antagonizes TGF-β in vivo.

Immune cell recruitment after the NIR-boosted and MN-mediated cancer immunotherapy. Immune cell recruitment after the NIR-boosted and MN-mediated cancer.

NCMs regulate T cell survival in TLOs via PD-L1.

Fig. 5 Hypoxic tumors from obese mice associate with increased production of IL-6 by adipocytes and myeloid cells. Hypoxic tumors from obese mice associate.

Antitumor effect of local cancer immunotherapy treatment in various tumor models. Antitumor effect of local cancer immunotherapy treatment in various tumor.

CXCR5+/+ TFH cells are essential for the generation of LCMV-neutralizing antibodies and clearance of a persistent LCMV infection. CXCR5+/+ TFH cells are.

Fig. 2 AcPGP induces IL-8 and G-CSF release from human bronchial epithelial cells. AcPGP induces IL-8 and G-CSF release from human bronchial epithelial.

Cell viability tests. Cell viability tests. SEM images of (A) MC3T3-E1 cells and (B) MSCs on days 1, 3, and 5 of culture. (C) Survival rates of MC3T3-E1.

Administration of necroptosis-targeting AAVs in conjunction within vivo promotes durable tumor clearance. Administration of necroptosis-targeting AAVs.

Engineered AAVs can be used to specifically induce necroptosis of tumor cells in vitro. Engineered AAVs can be used to specifically induce necroptosis.

Tumor control by necroptotic cells requires BATF3+cDC1 and CD8+leukocytes. Tumor control by necroptotic cells requires BATF3+cDC1 and CD8+leukocytes. (A)

Antigen-specific immune responses are enhanced in hypertension.

Fig. 1. MSCs undergo in vivo apoptosis after infusion without affecting immunosuppression. MSCs undergo in vivo apoptosis after infusion without affecting.

Fig. 4 Conditional KD of LVs in LYVE-1-Cre/iDTR mice attenuated UUO-induced lymphocyte expansion in both RDLN and spleen, intrarenal inflammatory infiltration,

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

Platelet-released serotonin contributes to hypothermia in mice undergoing HA-hIgG–dependent anaphylaxis. Platelet-released serotonin contributes to hypothermia.

Fig. 8 Combining M7824 with radiation or chemotherapy enhances antitumor efficacy. Combining M7824 with radiation or chemotherapy enhances antitumor efficacy.

Fig. 1 Examples of experimental stimuli and behavioral performance.

Vaccine MN confer protective innate and adaptive immunity.

Innate immune and fibrinolytic systems cooperate also during bacterial infections. Innate immune and fibrinolytic systems cooperate also during bacterial.

Dectin-1 regulates innate IL-13.

T cell–derived cytokines drive immune evasion.

Fig. 5 In vivo evaluation of F-insulin for treatment of type 1 diabetic minipig. In vivo evaluation of F-insulin for treatment of type 1 diabetic minipig.

Ado loss drives TNF-dependent immune evasion.

CypD-deficient mice are susceptible to Mtb infection.

Fig. 3 BMS blocks functional responses in primary immune cells driven by IL-23 and IL-12. BMS blocks functional responses in primary immune.

Fig. 2 In situ vaccination of CpG in combination with anti-OX40 antibody cures established local and distant tumors. In situ vaccination of CpG in combination.

BMS blocks functional responses in primary immune cells driven by IFNα

Fig. 2 Extended local release of agonists of innate immunity prevents tumor recurrence and eliminates distal metastases. Extended local release of agonists.

Fig. 3 Local Maraba treatment of TNBC tumors provides long-term systemic protection. Local Maraba treatment of TNBC tumors provides long-term systemic.

Primary B16F10 tumor inhibits experimental metastasis formation in the lung. Primary B16F10 tumor inhibits experimental metastasis formation in the lung.

Pharmacological targeting of CDs promotes response to KRASG12C inhibition in vivo. Pharmacological targeting of CDs promotes response to KRASG12C inhibition.

Immune evasion occurs independently of perforin-mediated killing.

Fig. 4 Dox-CBD-SA treatment shows reduced toxicity.

Fig. 2 NDR2-deficient mice are more vulnerable to RNA viral infection.

Combination CDN and PD-L1 mAb treatment of established MOC1 tumors produces consistent tumor rejection. Combination CDN and PD-L1 mAb treatment of established.

Fig. 6 Antitumor effect on tumor growth and pulmonary metastasis of CSSD-9 in vivo. Antitumor effect on tumor growth and pulmonary metastasis of CSSD-9.

Chronic Treg reduction exacerbates bleomycin-induced skin fibrosis.

Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors. Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors.

Mechanisms of FRC-dependent myeloid cell recruitment.

Fig. 3 Comparisons of NDVI trends over the globally vegetated areas from 1982 to Comparisons of NDVI trends over the globally vegetated areas from.

Fibroblast activation in WT and NFATc2-deficient mice.

Fig. 1 RNA methyltransferase METTL14 and demethylase ALKBH5 promote growth and invasion of breast cancer cells. RNA methyltransferase METTL14 and demethylase.

Regulation of antibacterial B cell responses in the peritoneal cavity via MyD88 signaling in FRCs. Regulation of antibacterial B cell responses in the.

Fig. 3 Superiority of BAFF-R versus CD19-CAR T cells in a Burkitt lymphoma model is not due to greater tumor antigen density. Superiority of BAFF-R versus.

Fig. 3 Minimal treatment of ETL decreases metastatic burden and prolongs survival in the 4T1 breast carcinoma model after tumor resection. Minimal treatment.

γδ T cells producing IL-17 are required for short-term memory.

Fig. 6 Pharmacologic alterations of β-AR signaling regulate cardiomyocyte abscission and endowment. Pharmacologic alterations of β-AR signaling regulate.

Fig. 3 Evaluation of PTMAO immunogenicity.

CCR6 is dispensable for expansion of innate TCRαβ+ cells in oral candidiasis. CCR6 is dispensable for expansion of innate TCRαβ+ cells in oral candidiasis.

CSGG-induced iTreg cells are capable of suppressing intestinal inflammation. CSGG-induced iTreg cells are capable of suppressing intestinal inflammation.

Presentation transcript:

Immune-mediated tumor control by necroptotic cells requires NF-κB activation within dying cells but not MLKL-mediated cell lysis and DAMP release. Immune-mediated tumor control by necroptotic cells requires NF-κB activation within dying cells but not MLKL-mediated cell lysis and DAMP release. (A) Day 12 volumes of B16.F10-OVA tumors in various innate immune knock-out mice after necroptotic fibroblast injections on days 6, 8, and 10. n = 5 to 15 mice per group. (B) B16.F10-OVA tumor growth (left panel) and animal survival (right panel) upon coadministration of necroptotic fibroblasts with blocking α-CLEC9A antibody. n = 10 mice per group. (C and D) Tumor growth and overall survival after administration of lytic necrotic fibroblasts in (C) single or (D) contralateral B16.F10-OVA flank tumors. Tumor growth and survival curves for PBS, acCASP8, and acRIPK3 as presented in Fig. 1 and are also graphed for comparison. (E) B16.F10-OVA tumor growth curves after injection of necroptotic NIH 3T3 fibroblasts preincubated with the IκBα phosphorylation inhibitor BAY-117085, which prevents NF-κB activation in treated cells. n = 10 mice per group. (F) B16.F10-OVA tumor growth (left) and animal survival (right) after intratumoral injection of PBS, necroptotic fibroblasts, or MLKL−/− necroptotic fibroblasts. n = 7 to 9 mice per group. (G) Assessment of systemic inflammation via Luminex assay for inflammatory serum cytokines and chemokines 48 hours after intratumoral dying NIH 3T3 injection. DMXAA-injected mice were included as a positive control for systemic inflammatory cytokine production. The gray dashed line represents the limit of detection. n = 3 to 5 mice per group. (H) B16.F10-OVA tumor growth curves after intratumoral (IT), intraperitoneal (IP), distal subcutaneous (distal subQ), or intravenous (IV) injection of necroptotic fibroblasts. n = 7 to 9 mice per group. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. Black arrows indicate intratumoral dying cell injections. Error bars represent SEM. Data are pooled from two to five independent experiments. ns, not significant. Annelise G. Snyder et al. Sci. Immunol. 2019;4:eaaw2004 Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works